Treatment with TU produced a statistically significant reduction in HbA@c at @ and @ weeks and after a further @ weeks of open-label medication most marked in poorly controlled patients with baseline HbA@c greater than @ where the reduction was @ % within @ weeks , and a further @ % after @ weeks of open-label use .